Regeneron Pharmaceuticals Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Regeneron Pharmaceuticals Bundle
Visual. Strategic. Downloadable.
Curious where Regeneron’s portfolio sits — Stars, Cash Cows, Dogs, or Question Marks? This preview teases the story; the full BCG Matrix gives you quadrant-level placements, data-backed moves, and a clear playbook for capital allocation. Buy the complete report for a Word briefing plus an Excel summary you can drop into board decks and use today. Get instant access and cut straight to strategic clarity.
Stars
Dupixent franchise (with Sanofi)
Dupixent has seen massive, still-rising adoption across atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps and eosinophilic esophagitis, delivering over $10 billion in annual sales in 2024 and holding a leading share in markets that keep expanding. Continued investment in label expansions, payer access and supply is required to sustain and grow uptake. Holding share now compounds into a long-term powerhouse for Regeneron/Sanofi.
Eylea HD (aflibercept 8 mg) retina
Eylea HD (aflibercept 8 mg) has seen strong uptake in the evolving retina market by promising higher dose and fewer injections, a durability story supported by label claims of extended dosing intervals. Success hinges on heavy promotion and tight cadence with retina specialists plus real‑world outcomes data to counter switch pressure. If sustained, adoption can shift Eylea HD from a Star into Regeneron’s next major cash engine.
Libtayo oncology expansion
Libtayo has expanded labels across CSCC, BCC and NSCLC and is building combo momentum through 2024, positioning it as a BCG Matrix Star for Regeneron. The global oncology market exceeds $200 billion, so demand is growing even as competition intensifies. Sustaining growth requires heavy clinical investment and relentless field execution to defend share. Win share now and Libtayo can scale into a durable revenue pillar.
Inflammation growth wave (new Dupixent uses)
Dupixent is in a clear inflammation growth wave as approvals and label expansions in 2024 pushed it into pediatrics, earlier lines and adjacent allergic diseases, with annual Dupixent revenue exceeding $10 billion in 2024 and double-digit year-on-year uptake in new indications. Each approval feeds the same commercial channel, so wins compound customer reach but require ongoing trials, market education and payer negotiations. If launch velocity and uptake persist, the flywheel effect will sustain Stars-level growth.
- New populations: pediatrics, earlier lines, allergic comorbidities
- 2024 revenue: >$10B
- Needs: trials, education, payer work
- Risk/Reward: flywheel if velocity maintained
VelociSuite-driven bispecifics momentum
VelociSuite feeds multiple late-stage oncology bispecifics, positioning Regeneron as a Star with high innovation in T-cell engagers; R&D spend was about $2.1B in 2023, underpinning current cash burn. Trials remain capital-intensive but address a market with analysts estimating multibillion-dollar upside for bispecific T-cell engagers by 2030. Execution will determine if these assets become market leaders.
- Programs: multiple late-stage bispecifics
- R&D: ~$2.1B (2023)
- Market: multibillion-dollar T-cell engager opportunity by 2030
- Risk: high cash burn; reward: market leadership if executed
Four star assets: sustain clinical investment, payer work and field execution to scale
Dupixent >$10B (2024) and expanding indications; Eylea HD showing durability-driven uptake; Libtayo scaling across CSCC/BCC/NSCLC; VelociSuite enabling bispecific pipeline with R&D ~$2.1B (2023). All are Stars: high growth, high share, require continued clinical investment, payer work and field execution to convert into long-term cash engines.
| Asset | 2024/metric | Status | Need |
|---|---|---|---|
| Dupixent | >$10B | Star | Label, access |
| Eylea HD | Uptake | Star | Real-world data |
| Libtayo | Expanding labels | Star | Clinical combos |
| VelociSuite | R&D ~$2.1B (2023) | Star | Execution |
What is included in the product
Detailed Word Document
Regeneron BCG Matrix: pinpoints Stars (e.g., Eylea), Cash Cows, Question Marks and Dogs with invest, hold or divest guidance.
Customizable Excel Spreadsheet
One-page Regeneron BCG Matrix placing each unit in a quadrant to pinpoint pain points fast for executive decisions.
Cash Cows
Legacy Eylea (2 mg) retina
Legacy Eylea (2 mg) remains a cash cow for Regeneron with global net product sales of about $9.5 billion in 2024, backed by a large installed base and habitual prescribers that create predictable, recurring demand. Market growth has cooled to low single digits in 2024, yet Eylea’s share is entrenched, enabling lowish promotional spend versus launch assets. Focus is on milking efficiency while migrating patients to higher‑dose HD formulations on value-based positioning.
Ex‑US Eylea royalties (Bayer)
Ex‑US Eylea royalties via Bayer deliver reliable royalty checks from a mature global footprint; in 2024 this stream remains a core cash cow, generating hundreds of millions annually for Regeneron. Minimal incremental cost preserves margins. Royalties help fund the pipeline without heavy lift. Keep partner alignment and supply flawless to maintain the stream.
Dupixent profit share economics
Dupixent remains a scaled cash cow for Regeneron, with global Dupixent sales around $17.0 billion in 2024 and Regeneron capturing a sizable profit-share that supports high margins as the brand matures across markets. Promotion efficiency rises as awareness peaks, lowering customer-acquisition costs and boosting operating leverage. Cash generation funds R&D and BD while management must defend access, manage pricing pressure, and avoid complacency to sustain long-term value.
Kevzara in RA (steady niche)
Kevzara (sarilumab) in RA is a mature, steady niche as of 2024 with limited growth potential in the IL-6 inhibitor class; it requires modest field support and delivers predictable cash flow rather than blockbuster revenue. It is not a headline maker but remains dependable for portfolio stability; focus on cost optimization and streamlined promotion to preserve margins and minimize overhead.
- Mature category (approved 2017; stable positioning as of 2024)
- Limited growth, niche IL-6 share
- Generates recurring cash with modest field investment
- Not a growth driver—optimize costs and keep operations tidy
Platform and collaboration income
Platform and collaboration income from manufacturing, milestone and technology-driven payments provides Regeneron with low-growth, high-predictability cash flow that smooths the P&L and underwrites R&D experiments elsewhere.
- Manufacturing and milestone receipts stabilize revenues
- Technology-driven payments reduce volatility
- Funds strategic experiments
- Maintain partner pipeline and delivery SLAs
Major cash engines: $17.0B driver, $9.5B cash cow
Eylea 2 mg: ~$9.5B 2024 sales, entrenched cash cow; ex‑US royalties: hundreds of millions, high margin. Dupixent: ~$17.0B 2024, major cash generator funding R&D. Kevzara and platform/milestone income: steady, low‑growth cash flows; focus on cost efficiency and sustaining access.
| Asset | 2024 | Role |
|---|---|---|
| Eylea | $9.5B | Cash cow |
| Dupixent | $17.0B | Primary cash generator |
| Royalties/Platform | Hundreds MM | Stable cash |
What You See Is What You Get
Regeneron Pharmaceuticals BCG Matrix
The file you’re previewing is the final Regeneron Pharmaceuticals BCG Matrix you’ll receive after purchase. It maps Regeneron’s product portfolio into Stars, Cash Cows, Question Marks and Dogs with market-backed data and clear visuals. No watermarks or demo content—fully editable and presentation-ready. Buy once, download immediately, and use it straight in meetings or strategy decks.
Dogs
REGEN‑COV (COVID‑19 mAb)
REGEN‑COV received EUA in November 2020 but lost clinical utility against Omicron and related subvariants, prompting FDA guidance limiting its use in early 2022 and effectively eliminating U.S. demand. Regulatory constraints and viral evolution moved on, leaving commercial sales near zero since 2022 and creating a cash‑trap to maintain inventory and manufacturing readiness. Keep the asset minimal on the BCG matrix and redeploy capital and R&D to more durable Regeneron programs with sustained market potential.
Zaltrap oncology
Zaltrap (ziv-aflibercept; FDA approved 2012) shows chronic underperformance versus newer VEGF and IO combos, with limited clinician pull and no label expansions through 2024. In a mature mCRC market dominated by established regimens, Zaltrap is at best break-even and often seen as a commercial distraction. Candidate for continued de‑emphasis within Regeneron’s oncology portfolio.
Praluent (PCSK9) cholesterol
Praluent remains a BCG Dogs: low market share versus Amgen Repatha (2024 sales ~Regeneron $1.1B vs Amgen $2.0B), with persistent payer friction and prior-authorization barriers limiting uptake. Category growth is slow and price pressure is real as PCSK9 class expansion stalls and discounts rise. Effort rarely matches output; maintain only where unit economics and formulary positioning justify continued investment.
Deprioritized pain (e.g., fasinumab)
Deprioritized pain program (fasinumab) sits in Dogs: safety/benefit concerns seen through historical NGF joint-safety signals have dimmed commercial and regulatory outlook by 2024, making restart costly with low probability of clinical or market success; reviving would be a classic cash sink versus opportunity cost for Regeneron, so recommendation is to keep it dormant and redeploy resources.
- Tag: safety
- Tag: high restart cost
- Tag: low win probability
- Tag: cash sink if revived
- Tag: keep shut, move on
Older, small legacy SKUs
Older, small legacy SKUs tie up resources with negligible growth and, despite Regeneron reporting approximately $12.5bn net product sales in 2024, these tails neither earn nor burn meaningfully but clog commercial focus; a brand refresh is unlikely to change the sales curve. Trim and simplify the tail to reallocate spend to high-growth franchises and pipeline priorities.
- Low growth: legacy SKUs <3% of 2024 net product sales
- Opportunity cost: reallocates marketing/R&D spend
- Action: prune SKUs, simplify supply chain
Prune low performers; redeploy capital - legacy SKUs under 3% of $12.5B
REGEN‑COV, Praluent, Zaltrap and fasinumab are BCG Dogs: REGEN‑COV sales near zero since 2022; Praluent ~Regeneron $1.1B vs Amgen $2.0B (2024); Zaltrap dated (FDA 2012) with limited traction; fasinumab high restart cost and low win probability. Legacy SKUs <3% of 2024 $12.5B net product sales—prune and redeploy capital.
| Asset | 2024/data | Action |
|---|---|---|
| REGEN‑COV | Sales ≈0 since 2022 | Minimize |
| Praluent | $1.1B vs Repatha $2.0B | De‑emphasize |
| Zaltrap | FDA 2012; underperforming | Prune |
| Fasinumab | High restart cost | Keep dormant |
| Legacy SKUs | <3% of $12.5B | Trim |
Question Marks
Odronextamab (CD20xCD3) NHL
Odronextamab (CD20xCD3) sits in a hot NHL category with clear unmet need and competitor proof points—epcoritamab gained FDA approval in 2023 and mosunetuzumab (Lunsumio) earlier—while Regeneron’s commercial share is effectively zero today. Early Phase 2 data reported encouraging response rates, but rapid approvals, clear differentiation versus approved bispecifics, and tight safety management are essential. Given a global NHL market ~6.8 billion in 2024, strategy should be invest to win or exit fast.
Linvoseltamab (BCMAxCD3) myeloma
Linvoseltamab sits as a Question Mark in Regeneron’s BCG matrix amid a crowded, fast-moving BCMA field anchored by approvals such as teclistamab and cilta-cel (2022–23); the MM incidence of roughly 160–180k new global cases annually suggests a large growth runway. Differentiation in dosing, CRS profile, and durability will determine commercial viability; heavy trial and launch spend is likely, so go bold if early safety and durability signals hold.
Evinacumab (HoFH and beyond)
Evinacumab (Evkeeza) sits in Question Marks: approved for HoFH in 2021 and addressing an ultra-rare population (~1 in 160,000–300,000), so current market share is inherently low despite marked LDL-C reductions and clear clinical value for responders. Label expansions or positive Phase III/real-world data could materially enlarge addressable market. Access and underdiagnosis are choke points; invest in diagnostic programs and payer/evidence generation to convert rarity into scalable revenue.
Libtayo combo pipeline (e.g., LAG‑3 partner)
Libtayo combo with LAG‑3 sits in Question Marks: combo science can unlock larger solid‑tumor indications but pivotal proof remained pending in 2024, with >5 active Phase 1/2 combo trials and no registrational readouts yet. Spend is high, shifting Regeneron R&D focus and capital allocation; outcomes uncertain. If clear synergy emerges it flips to Star; absent efficacy, rapid cut is warranted.
- Trials: >5 active Phase1/2 combos (2024)
- Risk: high spend, uncertain readouts
- Decision: promote if synergy; terminate if no benefit
Genetics/RNAi and gene editing tie‑ups
Genetics/RNAi and gene‑editing tie‑ups are question marks for Regeneron: first‑in‑class upside is large but as of 2024 there are no commercial products or meaningful market share from these modalities. Development timelines remain multi‑year and capital intensive, making these strategic bets rather than sure things. Management should double down on candidates showing robust clinical validation and prune programs that fail to de‑risk.
- Big upside, zero commercial share (2024)
- Long timelines, high capital intensity
- Strategic bets — not guaranteed
- Double down on validated winners; prune others
Phase2+ bets only: high upside, limited share — back differentiation or payer-enabled plays
Question Marks: high upside but low share; invest selectively where Phase2+ signals, differentiation, or label expansion can capture portions of 2024 markets (NHL $6.8B; MM 160–180k new cases; HoFH prevalence ~1:160k–300k).
| Asset | Stage | Key 2024 datapoint | Decision |
|---|---|---|---|
| Odronextamab | Ph2 | NHL market $6.8B | Invest if differentiation |
| Linvoseltamab | Ph2 | MM incidence 160–180k | Bold spend if safety/durability |
| Evinacumab | Approved | HoFH 1:160k–300k | Invest diagnostic/payer |
| Libtayo+LAG‑3 | Ph1/2 combos | >5 active combos (2024) | Promote if synergy |
| Genetics/RNAi | Precommercial | Zero revenue (2024) | Double down on validated |